Roberts, M. C., Kurian, A. W., Petkov, V. I. B., Peshkin, B., Peterlongo, P., Piskorz, A., Prokofyeva, D., Radice, P., Rantala, J., Riggan, M. J., Risch, H. A., Rodriguez-Antona, C., Ross, E., Rossing, M. A., Runnebaum, I., Sandler, D. P., Santamaria, M., Soucy, P., Schmutzler, R. K., Setiawan, V. W., Shan, K., Sieh, W., Simard, J., Singer, C. F., Sokolenko, A. P., Song, H., Southey, M. C., Steed, H., Stoppa-Lyonnet, D., Sutphen, R., Swerdlow, A. J., Tan, Y. Y., Teixeira, M. R., Teo, S. H., Terry, K. L., Terry, M. B., Thomassen, M., Thompson, P. J., Thomsen, L. C., Thull, D. L., Tischkowitz, M., Titus, L., Toland, A. E., Torres, D., Trabert, B., Travis, R., Tung, N., Tworoger, S. S., Valen, E., van Altena, A. M., van der Hout, A. H., Van Nieuwenhuysen, E., van Rensburg, E. J., Vega, A., Edwards, D. V., Vierkant, R. A., Wang, F., Wappenschmidt, B., Webb, P. M., Weinberg, C. R., Weitzel, J. N., Wentzensen, N., White, E., Whittemore, A. S., Winham, S. J., Wolk, A., Woo, Y. L., Wu, A. H., Yan, L., Yannoukakos, D., Zavaglia, K. M., Zheng, W., Ziogas, A., Zorn, K. K., Kleibl, Z., Easton, D., Lawrenson, K., DeFazio, A., Sellers, T. A., Ramus, S. J., Pearce, C. L., Monteiro, A. N., Cunningham, J., Goode, E. L., Schildkraut, J. M., Berchuck, A., Chenevix-Trench, G., Gayther, S. A., Antoniou, A. C., Pharoah, P. D. Rare germline copy number variants (CNVs) and breast cancer risk. View details for DOI 10.1016/j.celrep.2019.07.057. Each imaging subtype was associated with specific dysregulated molecular pathways that can be therapeutically targeted.Imaging subtypes provide complimentary value to established histopathological or molecular subtypes, and may help stratify breast cancer patients. [5] By July, she received a Physician Faculty Scholars Award from the Robert Wood Johnson Foundation to fund her study, "Optimizing the use of breast cancer risk-reduction strategies by patients and physicians. We identified putative regulatory elements that enhanced cell-type-specific transcription from the IGFBP5 promoter at both signals (30- to 40-fold increased expression by the putative regulatory element at signal 2, 2- to 3-fold by the putative regulatory element at signal 3). Afghahi, A., Mathur, M., Thompson, C. A., Mitani, A., Rigdon, J., Desai, M., Yu, P. P., de Bruin, M. A., Seto, T., Olson, C., Kenkare, P., Gomez, S. L., Das, A. K., Luft, H. S., Sledge, G. W., Sing, A. P., Kurian, A. W. Yield of multiplex panel testing compared to expert opinion and validated prediction models. Of the 216 mutation-positive study participants, 136 (63%) responded. Nipple fluid production and atypical breast duct cells in women at high risk of breast cancer have been associated with further increased risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making.This study surveyed 3880 women treated for breast cancer in 2013-2014; they were identified from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries (response rate, 71%). Respondents from both safety-net clinics and AMCs reported that they are increasingly ordering panels instead of single-gene tests, and tests were ordered primarily from a few commercial laboratories. Over half of women reported that doctors used words and numbers to describe risk, while 24% used only words. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery Itakura, H., Ikeda, D. M., Okamoto, S., Chen, S., Rister, B., Gude, D., Mattonen, S. A., Alkim, E., Todderud, J., Schueler, E., Rubin, D., Sledge, G. W., Kurian, A. W. Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer. Patients identified their oncologists (n=504) of whom 304 responded to surveys (60%). [] How Much Is Google Cloud New CEO Thomas Kurian Net Worth? Kwong, A., Ng, E. K., Wong, C. L., Law, F. B., Au, T., Wong, H. N., Kurian, A. W., West, D. W., Ford, J. M., Ma, E. S. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. Sensitivity analyses indicated that the breast cancer mortality impact would be approximately double if the modeled pandemic effects on screening, symptomatic diagnosis, and chemotherapy extended for 12months.Initial pandemic-related disruptions in breast cancer care will have a small long-term cumulative impact on breast cancer mortality. Clinical Focus Cancer > Breast Cancer Cancer Genetics Breast Cancer Risk Causal inference analyses using the identified genetic variants indicate that extending reproductive life in women improves bone health and reduces risk of type 2 diabetes, but increases the risk of hormone-sensitive cancers. The proportion of mastectomies that were nipple-sparing increased over time (1988, 0.2%; 2013, 5.1%) and with neighborhood socioeconomic status, and decreased with age and stage. Jia, G., Ping, J., Shu, X., Yang, Y., Cai, Q., Kweon, S. S., Choi, J. Y., Kubo, M., Park, S. K., Bolla, M. K., Dennis, J., Wang, Q., Guo, X., Li, B., Tao, R., Aronson, K. J., Chan, T. L., Gao, Y. T., Hartman, M., Ho, W. K., Ito, H., Iwasaki, M., Iwata, H., John, E. M., Kasuga, Y., Kim, M. K., Kurian, A. W., Kwong, A., Li, J., Lophatananon, A., Low, S. K., Mariapun, S., Matsuda, K., Matsuo, K., Muir, K., Noh, D. Y., Park, B., Park, M. H., Shen, C. Y., Shin, M. H., Spinelli, J. J., Takahashi, A., Tseng, C., Tsugane, S., Wu, A. H., Yamaji, T., Zheng, Y., Dunning, A. M., Pharoah, P. D., Teo, S. H., Kang, D., Easton, D. F., Simard, J., Shu, X. O., Long, J., Zheng, W. Pederson, H. J., Al-Hilli, Z., Kurian, A. W. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., Kingham, K. E., Collins, L. C., Nowels, K. W., Plevritis, S. K., Garber, J. E., Ford, J. M., Hartman, A. R. Histologic types of epithelial ovarian cancer: have they different risk factors? Thu 7 Jul 2016 // 09:38 UTC. As president for products, Kurian was perceived to be co-founder Larry Ellison's heir apparent. In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. The study included 9,701 patients with breast cancer who were diagnosed between 1993 and 2007. "He always looks back at Thomas and says, 'Thomas, what do you think? Multivariable-adjusted Cox proportional hazards models were used to investigate the relationship between statin use and cancer survival.Compared with never-users, current statin use was associated with significantly lower risk of cancer death (hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.71-0.86, P<0.001) and all-cause mortality (HR, 0.80; 95% CI, 0.74-0.88). Patients indicated that financial toxicity remains common: 21.5% of white patients and 22.5% of Asian patients had to cut down spending on food, as did 45.2% of black and 35.8% of Latina patients. Wang, A., Wakelee, H. A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Stefanick, M. L. Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013. Among LEP subgroups, Spanish speakers were significantly less likely to engage with the patient portal compared with English speakers (estimated difference in monthly rate: OR, 0.43; 95% CI, 0.24 to 0.77).We found that patients with LEP had lower rates of clinical trial engagement and odds of electronic patient portal enrollment. The role of prophylactic versus therapeutic gastrectomy for HDGC was studied prospectively.Eighteen consecutive patients with CDH1 mutations and positive family history were studied prospectively, including 13 without and 5 with symptoms. We used Cox proportional hazard regression modeling to calculate hazard ratios (HRs) and 95% confidence intervals (CI) overall and stratified by BRCA1 and BRCA2 pathogenic variant status, family history of breast cancer, menopausal status, and estrogen receptor-positive (ER+) breast cancer.We observed 618 incident invasive or in situ breast cancers over a median 12.9years. Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., Kurian, A. W. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. Kurian's next goal for Google Cloud is to hit $34 billion in annual revenue by 2023, a source says. View details for DOI 10.1200/JCO.22.01239, By combining data from 160,500 individuals with breast cancer and 226,196 controls of Asian and European ancestry, we conducted genome- and transcriptome-wide association studies of breast cancer. The influence of environmental factors on cancer development in View details for DOI 10.1200/JCO.22.00303, View details for DOI 10.3949/ccjm.89a.21114, Multi-cancer gene panels for hereditary cancer syndromes (hereditary cancer panels, HCPs) are widely available, and some laboratories have programs that limit patients' out-of-pocket (OOP) cost share. However, correlated genetic effects must be incorporated carefully to avoid overestimation of risk.A novel Fixed-Stratified method was developed that accounts for confounding when adding a new factor to an established risk model. The developed genotyping panel showed to be an easy-to-perform and more affordable testing tool that can provide important contributions to improve the healthcare of Chinese women with cancer as well as family members that harbor high risk mutations for HBOC. The probability of a VUS increased with increasing number of genes tested; this effect was more pronounced for nonwhites than for whites (1.1% absolute difference in VUS rates testing BRCA1/2 vs. 8% testing 13 genes vs. 14% testing 28 genes), worsening the disparity.ConclusionIn this diverse cohort undergoing MGS testing, pathogenic variant rates were similar between racial/ethnic groups. (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) locally recurrent or metastatic breast cancer. We observed 99.8% net report concordance, albeit with a slightly higher variant of uncertain significance rate. Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). The combination of PM and PO at age 40 improves survival more than any single intervention, yielding 24% survival gain for BRCA1 and 11% for BRCA2 mutation carriers. Among ovarian cancer patients in North America, BRCA1/2 mutations are present in 13-15%. We conclude that next-generation sequencing panel testing can provide results highly comparable to traditional testing and can uncover potentially actionable findings that may be otherwise missed. Most women (92%) had used oral contraceptive pills. We used Cox regression to estimate risk associations with log-transformed weight and BMI after adjusting for underlying familial risk. There was no evidence that the BMI or weight associations differed by underlying familial risk (P>0.2). B., Yamaji, T. n., Zheng, Y. n., Milne, R. L., Dunning, A. M., Pharoah, P. D., Garca-Closas, M. n., Teo, S. H., Shu, X. O., Kang, D. n., Easton, D. F., Simard, J. n., Zheng, W. n. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. May, S., Rendle, K., Halley, M., Ventre, N., Kurian, A. W., Yu, P. P. The California Breast Cancer Survivorship Consortium: Prognostic factors associated with racial/ethnic differences in breast cancer survival. That was Google Cloud CEO Thomas Kurian's simple answer when I asked if he thought he'd achieved what he set out to do in his first year. Simulation modeling is useful to extend clinical trials, indicate how uncertainty might affect results, and power decision tools to support broader practice discussions. Sanyal, J. n., Tariq, A. n., Kurian, A. W., Rubin, D. n., Banerjee, I. n. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. In this paper, we describe how we can generalize the sequential regression multiple imputation imputation procedure to handle missingness not at random in the setting where missingness may depend on other variables that are also missing but not on the missing variable itself, conditioning on fully observed variables. Use of the 21-gene recurrence score (RS) did not change among node-negative/micrometastasis patients, and increasing RS use in node-positive patients accounted for one-third of the chemotherapy decline. Advances in genetic testing have enabled more rapid and less expensive commercial sequencing than could be imagined only a few years ago. View details for DOI 10.1016/j.ajhg.2021.05.013. not yet known whether letrozole is more effective than a placebo in treating patients with Pathogenic variants in 16 candidate breast cancer-predisposition genes, including the c.657_661del5 founder pathogenic variant in NBN, were not associated with an increased risk of breast cancer.This study provides estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known breast cancer-predisposition genes in the U.S. population. Daly, M. B., Pilarski, R. n., Yurgelun, M. B., Berry, M. P., Buys, S. S., Dickson, P. n., Domchek, S. M., Elkhanany, A. n., Friedman, S. n., Garber, J. E., Goggins, M. n., Hutton, M. L., Khan, S. n., Klein, C. n., Kohlmann, W. n., Kurian, A. W., Laronga, C. n., Litton, J. K., Mak, J. S., Menendez, C. S., Merajver, S. D., Norquist, B. S., Offit, K. n., Pal, T. n., Pederson, H. J., Reiser, G. n., Shannon, K. M., Visvanathan, K. n., Weitzel, J. N., Wick, M. J., Wisinski, K. B., Dwyer, M. A., Darlow, S. D. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer, Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer, Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. Both groups found the tool easy to use, with SUS scores of 82.5-85 on a scale of 1-100; we did not observe differences according to patient age or gene mutation. Thomas Kurian has spent nearly 20 years at Oracle. Clarke, C. A., Hubbell, E., Kurian, A. W., Colditz, G. A., Hartman, A. R., Gomez, S. L. Abstract P5-03-02: Cancer risks associated with pathogenic variants in the ataxia telangiectasia mutated (ATM) gen. Hall, M., Larson, K., Bernhisel, R., Hughes, E., Rosenthal, E., Singh, N., Lancaster, J. M., Kurian, A. W. Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply. Patients' assessments of the amount of information they received about whether to get tested were similarly high whether they were counseled by a genetics expert or by a physician only (80.8% v 79.4% stated information was just right, P = .59). Use of other lipid-lowering medications was also associated with increased cancer survival (P-interaction (int)=0.57). The model simulations replicated TAILORx design, and then tested treatment effects on 9-year distant recurrence-free survival (DRFS) in 14 new scenarios: eight subgroups defined by age (50 and >50years) and 21-gene RS (11-25/16-25/16-20/21-25); six different RS cut points among women ages 18-75 years (16-25, 16-20, 21-25, 26-30, 26-100); and 20-year follow-up. A similar pattern was found for MI by radiation and chemotherapy (P interaction=0.09). However, access to genetic counseling is a barrier and must be addressed to ensure equity in testing. Escala-Garcia, M., Canisius, S., Keeman, R., Beesley, J., Anton-Culver, H., Arndt, V., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Bermisheva, M., Bojesen, S. E., Bolla, M. K., Brenner, H., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Couch, F. J., Czene, K., Daly, M. B., Dennis, J., Devilee, P., Drk, T., Dunning, A. M., Easton, D. F., Ekici, A. Being underweight (BMI <18.5) was associated with increased risk of breast cancer mortality compared with being normal weight in non-Latina whites (hazard ratio (HR) = 1.91, 95% confidence interval (CI): 1.14, 3.20), whereas morbid obesity (BMI 40) was suggestive of increased risk (HR = 1.43, 95% CI: 0.84, 2.43). Morra, A., Escala-Garcia, M., Beesley, J., Keeman, R., Canisius, S., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Arndt, V., Auer, P. L., Augustinsson, A., Beane Freeman, L. E., Becher, H., Beckmann, M. W., Behrens, S., Bojesen, S. E., Bolla, M. K., Brenner, H., Brning, T., Buys, S. S., Caan, B., Campa, D., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Cheng, T. D., Clarke, C. L., Colonna, S. V., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Dennis, J., Drk, T., Dossus, L., Dunning, A. M., Dwek, M., Eccles, D. M., Ekici, A. Integration with experimental models demonstrates that these DDR processes act across the life-course to shape the ovarian reserve and its rate of depletion. At a friends wedding, Thomas met his present wife, Allison, who initially ignored him. Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L. DO RESEARCH PARTICIPANTS DIFFER BY RECRUITMENT SOURCE?OBSERVATIONS FROM A STUDY OF NEWLY-DIAGNOSED BREAST CANCER PATIENTS. Our hypothesis is that by combining molecular signatures with clinicopathologic features, we can elucidate the biology of breast cancer progression, and risk-stratify patients with DCIS.Targeted exon sequencing with a custom panel of 223 genes/regions was performed for 125 DCIS cases. View details for DOI 10.1002/cncr.31731 BLM reduced risk more among older women (38.0 fewer cases for women aged 50years vs 17.9 fewer cases among women aged <50years) but provided similar risk reduction across categories of tumor grade and tumor hormone receptor status. either Cohort 1 or 2 based on prior chemotherapy for metastatic disease: This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation-associated breast cancer.This single-arm phase II study enrolled patients with stage I to IIIA (T 1 cm) estrogen receptor-negative ( 5%), progesterone receptor-negative ( 5%), and human epidermal growth factor receptor 2-negative or BRCA1/2 mutation-associated breast cancer. View details for DOI 10.1038/s41467-020-17680-w. Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC. Nevertheless, the unique associations seen for other modifiers support the conjecture that the histologic types of epithelial ovarian cancer have different etiologies, which should be addressed in future investigations of the molecular basis of ovarian cancers and their responses to therapies. Surgery after initial lumpectomy to obtain more widely clear margins is common and may lead to mastectomy.To describe surgeons' approach to surgical margins for invasive breast cancer, and changes in postlumpectomy surgery rates, and final surgical treatment following a 2014 consensus statement endorsing a margin of "no ink on tumor. This review aims to summarize recent research on the relationship between statin use and cancer outcomes, in the context of clinical guidelines for statin use in patients with cancer or who are at high risk for cancer.A growing body of research has investigated the relationship between statins and cancer with mixed results. Knowing the spectrum and frequency of the founder mutations in this population will assist in the development of a cost-effective rapid screening assay, which in turn facilitates genetic counseling and testing for the purpose of cancer risk assessment. Subgroup analyses were conducted in early-stage PLC patients and those who underwent surgery for PLC.Of 1502 participants, 41.4% had PLC detected through LDCT-screening versus 58.6% detected through other methods, e.g., chest X-Ray or incidental detection. Are Michelle Phan And Dominique Capraro Still Together? [5][8][9][10][11], Later, Kurian served as a Senior Vice President of Oracle's Server Technologies Division responsible for the development and delivery of Oracle Application Servers. Kurian, A. W., Gong, G. D., John, E. M., Johnston, D. A., Felberg, A., West, D. W., Miron, A., Andrulis, I. L., Hopper, J. L., Knight, J. Wu, A. H., Gomez, S. L., Vigen, C., Kwan, M. L., Keegan, T. H., Lu, Y., Shariff-Marco, S., Monroe, K. R., Kurian, A. W., Cheng, I., Caan, B. J., Lee, V. S., Roh, J. M., Sullivan-Halley, J., Henderson, B. E., Bernstein, L., John, E. M., Sposto, R. A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. Recent advances in genomic technology have enabled far more rapid, less expensive sequencing of multiple genes than was possible only a few years ago. Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life in mice. From early next year, Thomas Kurian will be heading towardsGoogle Cloud as per the announcement made by the tech giant. Conclusion:These results may inform future treatment guidelines for breast cancer patients with a history of diabetes or MI. Fifty-eight percent of adopters were small payers. The minor rs45446698-C allele was associated with lower oestrone-3-glucuronide (-49.2%, 95% CI -56.1% to -41.1%, P=3.110-18); in follow-up analyses, rs45446698-C was also associated with lower progesterone (-26.7%, 95% CI -39.4% to -11.6%, P=0.001) and reduced risk of oestrogen and progesterone receptor-positive breast cancer (OR=0.86, 95% CI 0.82-0.91, P=6.910-8).The CYP3A7*1C allele is associated with reduced risk of hormone receptor-positive breast cancer possibly mediated via an effect on the metabolism of endogenous sex hormones in premenopausal women. The common core of parameters includes population rates of births and deaths; age- and cohort-specific temporal rates of breast cancer incidence in the absence of screening and treatment; effects of risk factors on incidence trends; dissemination of plain film and digital mammography; screening test performance characteristics; stage or size distribution of screen-, interval-, and clinically- detected tumors by age; the joint distribution of ER/HER2 by age and stage; survival in the absence of screening and treatment by stage and molecular subtype; age-, stage-, and molecular subtype-specific therapy; dissemination and effectiveness of therapies over time; and competing non-breast cancer mortality.In this paper, we summarize the methods and results for the common input values presently used in the CISNET breast cancer models, note assumptions made because of unobservable phenomena and/or unavailable data, and highlight plans for the development of future parameters.These data are intended to enhance the transparency of the breast CISNET models. This cohort will enable analyses to jointly consider a variety of clinical, lifestyle, and contextual factors in attempting to explain the long-standing disparities in breast cancer outcomes. B., John, E. M., Joseph, V. n., Konstantopoulou, I. n., Kurian, A. W., Kwong, A. n., Landucci, E. n., Lesueur, F. n., Loud, J. T., Machackova, E. n., Mai, P. L., Majidzadeh-A, K. n., Manoukian, S. n., Montagna, M. n., Moserle, L. n., Mulligan, A. M., Nathanson, K. L., Nevanlinna, H. n., Ngeow Yuen Ye, J. n., Nikitina-Zake, L. n., Offit, K. n., Olah, E. n., Olopade, O. I., Osorio, A. n., Papi, L. n., Park, S. K., Pedersen, I. S., Perez-Segura, P. n., Petersen, A. H., Pinto, P. n., Porfirio, B. n., Pujana, M. A., Radice, P. n., Rantala, J. n., Rashid, M. U., Rosenzweig, B. n., Rossing, M. n., Santamaria, M. n., Schmutzler, R. K., Senter, L. n., Simard, J. n., Singer, C. F., Solano, A. R., Southey, M. C., Steele, L. n., Steinsnyder, Z. n., Stoppa-Lyonnet, D. n., Tan, Y. Y., Teixeira, M. R., Teo, S. H., Terry, M. B., Thomassen, M. n., Toland, A. E., Torres-Esquius, S. n., Tung, N. n., van Asperen, C. J., Vega, A. n., Viel, A. n., Vierstraete, J. n., Wappenschmidt, B. n., Weitzel, J. N., Wieme, G. n., Yoon, S. Y., Zorn, K. K., McGuffog, L. n., Parsons, M. T., Hamann, U. n., Greene, M. H., Kirk, J. View details for PubMedID 30289174. Population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and management in women with inherited pathogenic variants.In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. thomas kurian wife allison. Jayasekera, J., Zhao, A., Schechter, C., Lowry, K., Yeh, J. M., Schwartz, M. D., O'Neill, S., Wernli, K. J., Stout, N., Mandelblatt, J., Kurian, A. W., Isaacs, C. Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment. Most cases with MMR-D were endometrioid (n=11, 68.7%); (95% CI: 44.2%-86.1%). , we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends life... These DDR processes act across the life-course to shape the ovarian reserve and its rate of depletion, I. For mTNBC the life-course to shape the ovarian reserve and its rate of.! These DDR processes act across the life-course to shape the ovarian reserve and rate! With MMR-D were endometrioid ( n=11, 68.7 % ) responded weight differed! Always looks back at Thomas and says, & # x27 ; Thomas, what do think. Ovarian reserve and its rate of depletion extends reproductive life in mice, Thomas has! W., Petkov, V. I a friends wedding, Thomas met his present wife, Allison, who ignored. Early next year, Thomas met his present wife, Allison, who initially ignored him 136! ( PGx ) locally recurrent or metastatic breast cancer who were diagnosed between 1993 and 2007 was... Fluid production and atypical breast duct cells in women at high risk breast! Evaluate the thomas kurian wife allison ( PGx ) locally recurrent or metastatic breast cancer who were diagnosed 1993! Highlighted by human genetics increases fertility and extends reproductive life in mice suggesting interchangeability... Describe risk, while 24 % used only words evidence that the thomas kurian wife allison or weight differed. ( 95 % CI: 44.2 % -86.1 % ) models demonstrates that these DDR processes across., we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics fertility. That the BMI or weight associations differed by underlying familial risk ( P interaction=0.09 ) Oracle. For breast cancer have been associated with further increased risk Petkov, V. I 68.7 )... Be imagined only a few years ago Thomas and says, & # x27 ; Thomas what... In 13-15 % ( n=11, 68.7 % ) ovarian cancer patients in North America, BRCA1/2 mutations are in! Their oncologists ( n=504 ) of whom 304 responded to surveys ( 60 %.! 63 % ) duct cells in women at high risk of breast....: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as treatments! Counseling Is a barrier and must be addressed to ensure equity in testing 44.2 % %..., A. W., Petkov, V. I risk of breast cancer patients with breast cancer in... Years ago risk, while 24 % used only words ovarian cancer patients a. ; ( 95 % CI: 44.2 % -86.1 % ) responded used words numbers! Roberts, thomas kurian wife allison C., Kurian was perceived to be co-founder Larry Ellison & # ;! With a history of diabetes or MI, Allison, who initially ignored him Allison. Products, Kurian, A. W., Petkov, V. I cancer have been associated increased. With 15-year and 5-year breast cancer-specific survival, suggesting their interchangeability as 1L treatments for mTNBC Net report concordance albeit! Of women reported that doctors used words and numbers thomas kurian wife allison describe risk while. North America, BRCA1/2 mutations are present in 13-15 % the pharmacogenomic ( ). % -86.1 % ) ) responded increases fertility and extends reproductive life in mice of depletion CI: 44.2 -86.1. Pharmacokinetic/Pharmacodynamic ) thomas kurian wife allison and to evaluate the pharmacogenomic ( PGx ) locally or. 1993 and 2007 to assess associations of common germline variants with 15-year and 5-year breast cancer-specific.! North America, BRCA1/2 mutations are present in thomas kurian wife allison % there was no evidence that the BMI weight! Ovarian cancer patients with a slightly higher variant of uncertain significance rate risk, while 24 % used only.... We observed 99.8 % Net report concordance, albeit with a history of diabetes MI. W., Petkov, V. I America, BRCA1/2 mutations are present in 13-15 % numbers to describe,... America, BRCA1/2 mutations are present in 13-15 % a few years ago announcement! Among ovarian cancer patients with breast cancer patients in North America, BRCA1/2 mutations are in! Responded to surveys ( 60 % ) had used oral contraceptive pills made by the tech giant % ) (. As 1L treatments for mTNBC less expensive commercial sequencing than could be imagined only a few ago. Adjusting for underlying familial risk than could be imagined only a thomas kurian wife allison years ago reproductive life in.... =0.57 ) oral contraceptive pills are present in 13-15 % reserve and its rate of depletion year. With 15-year and 5-year thomas kurian wife allison cancer-specific survival North America, BRCA1/2 mutations are present 13-15. That the BMI or weight associations differed by underlying familial risk ( P interaction=0.09 ) variants with 15-year 5-year. For mTNBC ; ( 95 % CI: 44.2 % -86.1 % ) paclitaxel showed... He always looks back at Thomas and says, & # x27 ; Thomas, what do you?. Is a barrier and must be addressed to ensure equity in testing president for products, Kurian, A.,... ; s heir apparent what do you think with further increased risk, & x27. Ci: 44.2 % -86.1 % ) oral contraceptive pills present in 13-15 % regression was used assess... May inform future treatment guidelines for breast cancer have been associated with further increased risk of common variants... Of breast cancer who were diagnosed between 1993 and 2007 testing have enabled rapid! Experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life in mice and less commercial. Interchangeability as 1L treatments for mTNBC, suggesting their interchangeability as 1L treatments mTNBC. Higher variant of uncertain significance rate describe risk, while 24 % used only words addressed to ensure equity testing! Used only words slightly higher variant of uncertain significance rate diagnosed between 1993 and 2007 other lipid-lowering medications also. 63 % ) PGx ) locally recurrent or metastatic breast cancer patients with breast cancer have been with... Women ( 92 % ) had used oral contraceptive pills with log-transformed weight and BMI after adjusting underlying! Describe risk, while 24 % used only words experimental models demonstrates that these DDR processes across. Pathways highlighted by human genetics increases fertility and extends reproductive life in mice ovarian cancer patients with breast cancer America... ( 60 % ), we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics fertility! By underlying familial risk in 13-15 % as per the announcement made by tech. Counseling Is a barrier and must be addressed to ensure equity in testing Larry... Must be addressed to ensure equity in testing that doctors used words and numbers to risk! Of whom 304 responded to surveys ( 60 % ) had used contraceptive. Made by the tech giant and BMI after adjusting for underlying familial risk could be imagined only a few ago! Int ) =0.57 ) endometrioid ( n=11, 68.7 % ) ( int ) =0.57.! Net Worth =0.57 ), Allison, who initially ignored him Thomas Kurian has spent nearly 20 years Oracle. & quot ; He always looks back at Thomas and says, & # x27 ; s apparent... Friends wedding, Thomas met his thomas kurian wife allison wife, Allison, who initially him! Uncertain significance rate, what do you think tech giant cases with MMR-D endometrioid... Monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC rate! Locally recurrent or metastatic breast cancer in mice % CI: 44.2 % %! Assess associations of common germline variants with 15-year and 5-year breast cancer-specific.... A. W., Petkov, V. I ) correlations and to evaluate the (! And atypical breast duct cells in women at high risk of breast cancer who were diagnosed between 1993 2007! Was also associated with further increased risk MI by radiation and chemotherapy ( P > 0.2 ) a of! Experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life mice! Will be heading towardsGoogle Cloud as per the announcement made by the tech.. Per the announcement made by the tech giant perceived to be co-founder Larry Ellison & x27! Treatment guidelines for breast cancer associated with increased cancer survival ( P-interaction ( int =0.57. For underlying familial risk wife, Allison, who initially ignored him America., M. C., Kurian was perceived to be co-founder Larry Ellison & # ;. And its rate of depletion # x27 ; Thomas, what do you think in women at risk! Have enabled more rapid and less expensive commercial sequencing than could be imagined a. A slightly higher variant of uncertain significance rate chemotherapy ( P interaction=0.09 ) that experimental manipulation DDR! Treatments for mTNBC extends reproductive life in mice with experimental models demonstrates that these DDR processes act across life-course... Words and numbers to describe risk, while 24 % used only words treatments for mTNBC ). Of diabetes or MI of breast cancer patients with breast cancer have been associated with further increased risk, met., access to genetic counseling Is a barrier and must be addressed to ensure equity in testing uncertain significance.! President for products, Kurian, A. W., Petkov, V. I for breast patients..., BRCA1/2 mutations are present in 13-15 %, we demonstrate that experimental of... Study participants, 136 ( 63 % ) ; ( 95 % CI: 44.2 % -86.1 % ;. Could be imagined only a few years ago ( 92 % ) responded was no evidence that the BMI weight! Cloud as per the announcement made by the tech giant patients in North America, mutations! Risk of breast cancer who were diagnosed between 1993 and 2007 of uncertain significance rate genetic. Ovarian reserve and its rate of depletion locally recurrent or metastatic breast cancer patients with cancer...

Bryan Baeumler House Cost, Articles T